Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two toddlers playing happily

A paper published today in The Lancet Child & Adolescent Health provides standardised scores for The Parent Report of Children’s Abilities Revised (PARCA-R) questionnaire. The PARCA-R is recommended for routine use in the UK to screen for cognitive and language developmental delay in children born preterm and can be completed by parents in 10 to 15 minutes. A new website has also been launched (www.parca-r.info) with an online version of the questionnaire and a pre-programmed calculator for deriving the standardised scores.

Researchers at NPEU collaborated with colleagues at the University of Leicester, University College London, Warwick University and Birmingham University to standardise the PARCA-R. Anonymised data from over 6,000 PARCA-R questionnaires completed by parents of two-year old children in three previous studies were used as a standardisation sample. This sample was representative of the UK population in terms of sex, gestational age, multiple birth, ethnicity and socio-economic status. Anonymised data from three further studies were used to assess external validity of the standardised scores.

Standardisation of the PARCA-R will enable it to be used to quantify a child’s developmental level relative to the UK population of two-year olds, and identify advanced or delayed development. It is freely available for parents to use and has been translated into 14 languages, but standardised scores have, so far, only been developed for the original English version in the UK population.  Developmental assessment can be costly to administer and the PARCA-R provides a reliable, cost-effective alternative that could eventually be extended for use in low- and middle-income countries.